Oxytocin inhaled - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences

Drug Profile

Oxytocin inhaled - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences

Alternative Names: GR-121619; Heat-stable oxytocin - GlaxoSmithKline/Monash Institute of Pharmaceutical Sciences

Latest Information Update: 27 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Monash Institute of Pharmaceutical Sciences
  • Developer GlaxoSmithKline
  • Class Hormones; Oxytocics
  • Mechanism of Action Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Labour disorders

Most Recent Events

  • 01 Nov 2016 GlaxoSmithKline in collaboration with Monash University initiates enrolment in a phase I trial for Labour disorders in United Kingdom (NCT02999100)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Dec 2015 GlaxoSmithKline completes a phase I trial in Healthy female volunteers in United Kingdom (Inhalation) (NCT02542813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top